Ubiquitination of the transcription factor c-MAF is mediated by multiple lysine residues

International Journal of Biochemistry and Cell Biology

Volumn 57, Issue , 2014, Pages 157-166

  Chen, Guodong ^a   Xu, Xin ^a   Tong, Jiefei ^b   Han, Kunkun ^a   Zhang, Zubin ^a   Tang, Juan ^a   Li, Siyue ^a   Yang, Chuanqi ^a   Li, Jie ^a   Cao, Biyin ^a   Zhou, Haixia ^a   Wu, Depei ^a   Moran, Michael F ^b   Mao, Xinliang ^a  

^a SOOCHOW UNIVERSITY   (China)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

c MAF; Lysosome; Multiple myeloma; Proteasome; Ubiquitination

Indexed keywords

ARGININE; BORTEZOMIB; CYCLIN D2; CYCLOHEXIMIDE; LUCIFERASE; LYSINE; MESSENGER RNA; PROTEIN; TRANSCRIPTION FACTOR C MAF; MAF PROTEIN, HUMAN; PROTEASOME; UBIQUITIN;

AMINO ACID SUBSTITUTION; ARTICLE; BIOINFORMATICS; CELL ASSAY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE MUTATION; HELA CELL LINE; HUMAN; HUMAN CELL; LYSOSOME; MATHEMATICAL COMPUTING; MEDIATOR; MUTATIONAL ANALYSIS; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; UBIQUITINATION; AMINO ACID SEQUENCE; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; METABOLISM; MOLECULAR GENETICS; MULTIPLE MYELOMA; MUTATION; TUMOR CELL LINE;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; HEK293 CELLS; HELA CELLS; HUMANS; LYSINE; LYSOSOMES; MOLECULAR SEQUENCE DATA; MULTIPLE MYELOMA; MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-MAF; TRANSFECTION; UBIQUITIN; UBIQUITINATION;

EID: 84910051110     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2014.10.024     Document Type: Article

References (35)

1. Barbash O, Egan E, Pontano LL, Kosak J, Diehl JA. Lysine 269 is essential for cyclin D1 ubiquitylation by the SCF(Fbx4/alphaB-crystallin) ligase and subsequent proteasome-dependent degradation. Oncogene 2009;28:4317-25.
2. Batonnet S, Leibovitch MP, Tintignac L, Leibovitch SA. Critical role for lysine 133 in the nuclear ubiquitin-mediated degradation of MyoD. J Biol Chem 2004;279:5413-20.
3. Benkhelifa S, Provot S, Lecoq O, Pouponnot C, Calothy G, Felder-Schmittbuhl MP. mafA, a novel member of the maf proto-oncogene family, displays developmental regulation and mitogenic capacity in avian neuroretina cells. Oncogene 1998;17:247-54.
4. Chan WM, Mak MC, Fung TK, Lau A, Siu WY, Poon RY. Ubiquitination of p53 at multiple sites in the DNA-binding domain. Mol Cancer Res 2006;4:15-25.
5. Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T, et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998;91:4457-63.
6. Ciechanover A. Intracellular protein degradation: from a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting (Nobel lecture). Angew Chem Int Ed Engl 2005;44:5944-67.
7. Civil A, van Genesen ST, Lubsen NH. c-Maf, the gammaD-crystallin Maf-responsive element and growth factor regulation. Nucleic Acids Res 2002;30:975-82.
8. Dikic I, Wakatsuki S, Walters KJ. Ubiquitin-binding domains - from structures to functions. Nat Rev Mol Cell Biol 2009;10:659-71.
9. Fujiwara KT, Kataoka K, Nishizawa M. Two new members of the maf oncogene family, mafK and mafF, encode nuclear b-Zip proteins lacking putative transactivator domain. Oncogene 1993;8:2371-80.
10. Harmon JS, Stein R, Robertson RP. Oxidative stress-mediated, post-translational loss of MafA protein as a contributing mechanism to loss of insulin gene expression in glucotoxic beta cells. J Biol Chem 2005;280:11107-13.
11. Ho IC, Lo D, Glimcher LH. c-maf promotes T helper cell type 2 (Th2) and attenuates Th1 differentiation by both interleukin 4-dependent and -independent mechanisms. J Exp Med 1998;188:1859-66.
12. Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004;5:191-9.
13. Kataoka K, Fujiwara KT, Noda M, Nishizawa M. MafB, a new Maf family transcription activator that can associate with Maf and Fos but not with Jun. Mol Cell Biol 1994;14:7581-91.
14. Kataoka K, Igarashi K, Itoh K, Fujiwara KT, Noda M, Yamamoto M, et al. Small Maf proteins heterodimerize with Fos and may act as competitive repressors of the NF-E2 transcription factor. Mol Cell Biol 1995;15:2180-90.
15. Kusakabe M, Hasegawa K, Hamada M, Nakamura M, Ohsumi T, Suzuki H, et al. c-Maf plays a crucial role for the definitive erythropoiesis that accompanies erythroblastic island formation in the fetal liver. Blood 2011;118:1374-85.
16. Leavenworth JW, Ma X, Mo YY, Pauza ME. SUMO conjugation contributes to immune deviation in nonobese diabetic mice by suppressing c-Maf transactivation of IL-4. J Immunol 2009;183:1110-9.
17. Lin BS, Tsai PY, Hsieh WY, Tsao HW, Liu MW, Grenningloh R, et al. SUMOylation attenuates c-Maf-dependent IL-4 expression. Eur J Immunol 2010;40:1174-84.
18. Liu Q, Ji X, Breitman ML, Hitchcock PF, Swaroop A. Expression of the bZIP transcription factor gene Nrl in the developing nervous system. Oncogene 1996;12:207-11.
19. MacLean HE, Kim JI, Glimcher MJ, Wang J, Kronenberg HM, Glimcher LH. Absence of transcription factor c-maf causes abnormal terminal differentiation of hypertrophic chondrocytes during endochondral bone development. Dev Biol 2003;262:51-63.
20. Mao X, Cao B, Wood TE, Hurren R, Tong J, Wang X, et al. A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway. Blood 2011;117:1986-97.
21. Mao X, Seidlitz E, Ghosh K, Murakami Y, Ghosh HP. The cytoplasmic domain is critical to the tumor suppressor activity of TSLC1 in non-small cell lung cancer. Cancer Res 2003;6:7979-85.
22. Mao X, Stewart AK, Hurren R, Datti A, Zhu X, Zhu Y, et al. A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood 2007;110:4047-54.
23. Mao X, Zhu X, Hurren R, Ezzat S, Schimmer AD. Dexamethasone increases ubiquitin transcription through an SP-1 dependent mechanism in multiple myeloma cells. Leuk Res 2008;32:1480-2.
24. Morito N, Yoh K, Fujioka Y, Nakano T, Shimohata H, Hashimoto Y, et al. Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human. Cancer Res 2006;66:812-9.
25. Nishizawa M, Kataoka K, Goto N, Fujiwara KT, Kawai S. v-maf, a viral oncogene that encodes a "leucine zipper" motif. Proc Natl Acad Sci U S A 1989;86:7711-5.
26. Ring BZ, Cordes SP, Overbeek PA, Barsh GS. Regulation of mouse lens fiber cell development and differentiation by the Maf gene. Development 2000;127:307-17.
27. Robbiani DF, Colon K, Ely S, Ely S, Chesi M, Bergsagel PL. Osteopontin dysregulation and lytic bone lesions in multiple myeloma. Hematol Oncol 2007;25:16-20.
28. Rocques N, Abou Zeid N, Sii-Felice K, Lecoin L, Felder-Schmittbuhl MP, Eychene A, et al. GSK-3-mediated phosphorylation enhances Maf-transforming activity. Mol Cell 2007;28:584-97.
29. Sii-Felice K, Pouponnot C, Gillet S, Lecoin L, Girault JA, Eychene A, et al. MafA transcription factor is phosphorylated by p38 MAP kinase. FEBS Lett 2005;579:3547-54.
30. Suzuki A, Iida S, Kato-Uranishi M, Tajima E, Zhan F, Hanamura I, et al. ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. Oncogene 2005;24:6936-44.
31. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 2007;128:141-56.
32. Vinson C, Myakishev M, Acharya A, Mir AA, Moll JR, Bonovich M. Classification of human B-ZIP proteins based on dimerization properties. Mol Cell Biol 2002;22:6321-35.
33. Wang W, Nacusi L, Sheaff RJ, Liu X. Ubiquitination of p21Cip1/WAF1 by SCF-Skp2: substrate requirement and ubiquitination site selection. Biochemistry 2005;44:14553-64.
34. Wende H, Lechner SG, Cheret C, Bourane S, Kolanczyk ME, Pattyn A, et al. The transcription factor c-Maf controls touch receptor development and function. Science 2012;335:1373-6.
35. Zhang Z, Song L, Dong J, Guo D, Du X, Cao B, et al. A promising combo gene delivery system developed from (3-aminopropyl) triethoxysilane-modified iron oxide nanoparticles and cationic polymers; 2013. p. Springer, pp 1-11.